Production of interleukin-1-receptor antagonist during experimental endotoxaemia
- PMID: 1683422
- DOI: 10.1016/0140-6736(91)92725-h
Production of interleukin-1-receptor antagonist during experimental endotoxaemia
Abstract
Interleukin-1 (IL-1) has been implicated in the pathogenesis of sepsis. IL-1-receptor antagonist (IL-1ra) is a naturally occurring inhibitor of IL-1 activity that competes with IL-1 for occupancy of cell-surface receptors but possesses no agonist activity. We induced endotoxaemia in 9 healthy human volunteers by injection of Escherichia coli endotoxin, and measured plasma concentrations of IL-1 and IL-1ra by radioimmunoassay during the next 24 h. Peak plasma concentrations of IL-1ra were about a hundred-fold greater than those of IL-1 beta. No IL-1 or IL-1ra were detectable in the plasma of 4 volunteers injected with saline. Our results suggest that the predominant natural response to endotoxin in man is the production of antagonist rather than agonist.
Similar articles
-
Hematologic and immunomodulatory effects of an interleukin-1 receptor antagonist coinfusion during low-dose endotoxemia in healthy humans.Blood. 1993 Nov 15;82(10):2985-90. Blood. 1993. PMID: 8219190
-
Coordinated antiinflammatory effects of interleukin 4: interleukin 4 suppresses interleukin 1 production but up-regulates gene expression and synthesis of interleukin 1 receptor antagonist.Proc Natl Acad Sci U S A. 1992 May 1;89(9):4076-80. doi: 10.1073/pnas.89.9.4076. Proc Natl Acad Sci U S A. 1992. PMID: 1533284 Free PMC article.
-
Interleukin-1 receptor blockade improves survival and hemodynamic performance in Escherichia coli septic shock, but fails to alter host responses to sublethal endotoxemia.J Clin Invest. 1992 May;89(5):1551-7. doi: 10.1172/JCI115748. J Clin Invest. 1992. PMID: 1533231 Free PMC article.
-
Blocking IL-1: interleukin 1 receptor antagonist in vivo and in vitro.Immunol Today. 1991 Nov;12(11):404-10. doi: 10.1016/0167-5699(91)90142-G. Immunol Today. 1991. PMID: 1838480 Review.
-
IL-1ra: properties and uses of an interleukin-1 receptor antagonist.Agents Actions Suppl. 1991;35:41-9. Agents Actions Suppl. 1991. PMID: 1838233 Review. No abstract available.
Cited by
-
Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.J Infect Dis. 2015 Oct 1;212 Suppl 2(Suppl 2):S329-35. doi: 10.1093/infdis/jiv335. Epub 2015 Jul 23. J Infect Dis. 2015. PMID: 26209680 Free PMC article.
-
Rapid systemic surge of IL-33 after severe human trauma: a prospective observational study.Mol Med. 2021 Mar 26;27(1):29. doi: 10.1186/s10020-021-00288-1. Mol Med. 2021. PMID: 33771098 Free PMC article.
-
New insights into the biology of the acute phase response.J Clin Immunol. 1999 Jul;19(4):203-14. doi: 10.1023/a:1020563913045. J Clin Immunol. 1999. PMID: 10471974 Review.
-
Increased interleukin-1 (IL-1) and imbalance between IL-1 and IL-1 receptor antagonist during acute inflammation in experimental Shigellosis.Infect Immun. 1999 Nov;67(11):6056-66. doi: 10.1128/IAI.67.11.6056-6066.1999. Infect Immun. 1999. PMID: 10531267 Free PMC article.
-
Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein.J Clin Invest. 1997 Jun 15;99(12):2930-40. doi: 10.1172/JCI119488. J Clin Invest. 1997. PMID: 9185517 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources